Summary
This 8-K filing by Amgen Inc. (AMGN) primarily reports on the transition of Dr. Roger M. Perlmutter, Executive Vice President of Research and Development. Dr. Perlmutter retired from his executive role effective February 12, 2012. To leverage his expertise, Amgen has entered into a one-year consulting agreement with Perlmutter Consulting, Inc., ensuring continued advisory services on R&D matters. This arrangement allows Amgen to retain a key talent while managing the transition in leadership. The consulting agreement outlines specific terms for compensation and hours, including a quarterly fee and an hourly rate for additional services. This move is likely intended to ensure continuity and smooth handover of critical R&D initiatives, which is crucial for a biopharmaceutical company like Amgen that relies heavily on its product pipeline.
Key Highlights
- 1Dr. Roger M. Perlmutter, EVP of Research and Development, retired effective February 12, 2012.
- 2Amgen entered into a one-year consulting agreement with Perlmutter Consulting, Inc. (Dr. Perlmutter's entity) starting February 13, 2012.
- 3The agreement allows for a potential one-year extension.
- 4Dr. Perlmutter will provide advisory services on research and development and commercialization of the R&D product pipeline.
- 5Compensation includes $100,000 quarterly for up to 80 hours of service, plus an additional $1,200 per hour for services exceeding 80 hours (max 160 hours/quarter without prior authorization).
- 6Amgen will reimburse reasonable travel expenses incurred by Dr. Perlmutter.
- 7The agreement includes clauses regarding exclusivity of services and termination notice periods.